Kidney health may change how obesity drug works in body
NCT ID NCT06352411
First seen Nov 01, 2025
Summary
This study looks at how a single injection of BI 456906, a drug being developed for obesity and liver disease, behaves in the blood of people with different levels of kidney function. Researchers will compare drug levels in 42 adults with normal kidneys to those with mild, moderate, or severe kidney problems. The goal is to see if kidney impairment changes how much drug gets into the bloodstream, which could guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Kiel GmbH
Kiel, 24105, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 456906 (survodutide)
What this could lead to
If successful, this study could help doctors understand how to dose BI 456906 safely for people with kidney problems.
What could go wrong
This is an early-phase study with only 42 participants, so results may not apply to everyone. It focuses on drug levels, not on treating disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.